<DOC>
	<DOCNO>NCT00402350</DOCNO>
	<brief_summary>The Phase I clinical trial approximately 50 healthy volunteer conduct single clinical center two stage . Stage 1 open-label , cross-over comparison single dose Staccato Fentanyl equivalent dose intravenous ( IV ) fentanyl . Stage 2 randomize , doubleblind , placebo-controlled dose escalation Staccato Fentanyl , evaluate multiple dos fentanyl . The three primary aim Phase I clinical trial evaluate pharmacokinetics ( PK ) absolute bioavailability Fentanyl , compare Staccato Fentanyl PK profile IV fentanyl PK profile , examine tolerability safety Staccato Fentanyl non-opioid-tolerant , healthy volunteer population .</brief_summary>
	<brief_title>Staccato Fentanyl Single Multidose PK</brief_title>
	<detailed_description />
	<mesh_term>Breakthrough Pain</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>1 . Male female subject age 18 55 year , inclusive . 2 . Subjects body mass index ( BMI ) ≥ 21 ≤ 30 . 3 . Female subject pregnant , surgically sterile 2 year postmenopausal . If childbearing potential , must use medicallyaccepted method birth control agree continue use method least 30 day study ( i.e. , barrier method spermicide , steroidal contraceptive [ oral , transdermal , implanted , include DepoProvera ; contraceptive must use conjunction barrier method ] , intrauterine device ) . 4 . Subjects speak , read , understand English willing able provide write informed consent IRBapproved form prior initiation study procedure . 5 . Subjects willing able confine Clinical Research Unit ( CRU ) approximately 10 hour comply study schedule study requirement . 6 . Subjects good general health determine complete medical history , physical examination , 12lead ECG , spirometry , blood chemistry profile , hematology , urinalysis . 1 . Subjects regularly consume large amount xanthinecontaining substance ( i.e. , 5 cup coffee equivalent amount xanthinecontaining substance per day ) . 2 . Subjects take prescription nonprescription medication ( exception vitamin , acetaminophen , steroidal contraceptive woman childbearing potential medically necessary ) within 5 day Visits 2 3 . 3 . Subjects acute illness within 5 day either Visit 2 3 . 4 . Subjects receive investigational drug within 30 day ( within 5 half life investigational drug ) prior Visit 2 3 . 5 . Subjects smoke tobacco within last year . 6 . Subjects history within past 2 year drug alcohol dependence abuse define DSM4 . 7 . Subjects history HIV positivity . 8 . Subjects history allergy intolerance opioids . 9 . Subjects test positive alcohol positive urine drug screen study visit . 10 . Subjects hypotension ( systolic blood pressure ≤90 mmHg , diastolic blood pressure ≤50 mmHg ) , hypertension ( systolic blood pressure ≥140 mmHg , diastolic blood pressure ≥90 mmHg ) . 11 . Subjects clinically significant ECG abnormality ( beyond 1st degree heart block ) . 12 . Subjects history unstable angina , syncope , coronary artery disease , myocardial infarction , congestive heart failure ( CHF ) , stroke , transient ischemic attack ( TIA ) , significant neurological disorder . 13 . Subjects history pulmonary disease ( asthma , bronchitis , bronchospasm , emphysema ) . 14 . Subjects FEV1 le 80 % predict value spirometry assessment Visit 1 . 15 . Female subject breastfeed positive pregnancy test visit must exclude . 16 . Subjects disease condition , history , physical examination , laboratory abnormality investigator 's opinion , would present undue risk subject , may confound interpretation study result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Staccato Fentanyl , Pharmacokinetics , Pharmacodynamics , inhale fentanyl</keyword>
</DOC>